Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Intermountain Health Platte Valley Hospital — Brighton, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- UCHealth Memorial Hospital Central — Colorado Springs, Colorado
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Colorado: - Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- Saint Francis Cancer Center — Colorado Springs, Colorado
- CommonSpirit Cancer Center Mercy — Durango, Colorado
- Mercy Medical Center — Durango, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers - Boulder — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Centennial, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers, LLP — Denver, Colorado
- Rocky Mountain Cancer Centers, LLP — Denver, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Colorado: - University of Colorado Denver Anschultz Medical Campus — Aurora, Colorado
- Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Colorado: - University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087) — Fort Collins, Colorado
- Rocky Mountain Cancer Centers (RMCC) ( Site 8000) — Lone Tree, Colorado
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Colorado: - Rocky Mountain Cancer Center — Denver, Colorado
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Colorado: - University of Colorado Hospital-Anschutz Cancer Pavilion — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Colorado: - Rocky Mountain Cancer Center — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Colorado: - Rocky Mountain Cancer Center — Littleton, Colorado
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT06948448
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Colorado: - University of Colorado - Aurora Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Colorado: - Sarah Cannon Research Institute — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…
Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 2 Recruiting Academic/Other
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation…
Sponsor: University of Colorado, Denver
NCT ID: NCT07292298
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Colorado: - Exelixis Clinical Site #87 — Littleton, Colorado
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Colorado: - Clinical and Translational Research Center (CTRC) — Aurora, Colorado
- UCHealth Sue Anschutz-Rodgers Eye Center — Aurora, Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora, Colorado
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…
Sponsor: Pfizer
NCT ID: NCT06447662
Sites in Colorado: - University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora, Colorado
- University of Colorado Hospital - Anschutz Outpatient Pavilion — Aurora, Colorado
- University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
- University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT03715933
Sites in Colorado: - University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06131840
Sites in Colorado: - University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado
- University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Colorado: - University of Colorado - Aurora Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Sponsor: Incyte Corporation
NCT ID: NCT06179160
Sites in Colorado: - Sarah Cannon Research Institue At Healthone — Denver, Colorado